Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616662 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL10256486 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL8070420 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL13950543 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL20109261 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL17695897 | 0.84 | CYP1A2 (0.58) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL7519614 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL4038634 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL15083313 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL16289367 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3099686-B1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9777001-B2 | Macrocycles with aromatic P2′ groups as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3099686-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015116885-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015116885-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
| US-8940720-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
| US-20200087312-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | SMN1; SMN2 4133/4885CYP1A2 960/4885CYP2C9 709/4885 |
| US-20180022753-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3689/4885CYP1A2 1596/4885CYP2C9 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.